These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30259526)

  • 1. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.
    Suker M; Nuyttens JJ; Groot Koerkamp B; Eskens FALM; van Eijck CHJ
    J Surg Oncol; 2018 Nov; 118(6):1021-1026. PubMed ID: 30259526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
    Suker M; Beumer BR; Sadot E; Marthey L; Faris JE; Mellon EA; El-Rayes BF; Wang-Gillam A; Lacy J; Hosein PJ; Moorcraft SY; Conroy T; Hohla F; Allen P; Taieb J; Hong TS; Shridhar R; Chau I; van Eijck CH; Koerkamp BG
    Lancet Oncol; 2016 Jun; 17(6):801-810. PubMed ID: 27160474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
    Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
    BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity.
    Gunturu KS; Yao X; Cong X; Thumar JR; Hochster HS; Stein SM; Lacy J
    Med Oncol; 2013 Mar; 30(1):361. PubMed ID: 23271209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
    Faris JE; Blaszkowsky LS; McDermott S; Guimaraes AR; Szymonifka J; Huynh MA; Ferrone CR; Wargo JA; Allen JN; Dias LE; Kwak EL; Lillemoe KD; Thayer SP; Murphy JE; Zhu AX; Sahani DV; Wo JY; Clark JW; Fernandez-del Castillo C; Ryan DP; Hong TS
    Oncologist; 2013; 18(5):543-8. PubMed ID: 23657686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
    Chllamma MK; Cook N; Dhani NC; Giby K; Dodd A; Wang L; Hedley DW; Moore MJ; Knox JJ
    Br J Cancer; 2016 Sep; 115(6):649-54. PubMed ID: 27467054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
    Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
    Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
    Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
    Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
    Blazer M; Wu C; Goldberg RM; Phillips G; Schmidt C; Muscarella P; Wuthrick E; Williams TM; Reardon J; Ellison EC; Bloomston M; Bekaii-Saab T
    Ann Surg Oncol; 2015 Apr; 22(4):1153-9. PubMed ID: 25358667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.
    Kobayashi N; Shimamura T; Tokuhisa M; Goto A; Endo I; Ichikawa Y
    Medicine (Baltimore); 2017 May; 96(19):e6769. PubMed ID: 28489753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.
    Lakatos G; Petranyi A; Szűcs A; Nehéz L; Harsanyi L; Hegyi P; Bodoky G
    Pathol Oncol Res; 2017 Oct; 23(4):753-759. PubMed ID: 28062950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
    Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
    Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison.
    van Veldhuisen E; Vroomen LG; Ruarus AH; Derksen TC; Busch OR; de Jong MC; Kazemier G; Puijk RS; Sorgedrager NS; Vogel JA; Scheffer HJ; van Lienden KP; Wilmink JW; Besselink MG; Meijerink MR
    J Vasc Interv Radiol; 2020 Oct; 31(10):1600-1608. PubMed ID: 32861569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Clark JW; Jiang W; Yeap BY; Drapek LC; Ly L; Baglini CV; Blaszkowsky LS; Ferrone CR; Parikh AR; Weekes CD; Nipp RD; Kwak EL; Allen JN; Corcoran RB; Ting DT; Faris JE; Zhu AX; Goyal L; Berger DL; Qadan M; Lillemoe KD; Talele N; Jain RK; DeLaney TF; Duda DG; Boucher Y; Fernández-Del Castillo C; Hong TS
    JAMA Oncol; 2019 Jul; 5(7):1020-1027. PubMed ID: 31145418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome.
    Teriaca MA; Loi M; Suker M; Eskens FALM; van Eijck CHJ; Nuyttens JJ
    Radiother Oncol; 2021 Feb; 155():232-236. PubMed ID: 33217500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study.
    Vogel JA; Rombouts SJ; de Rooij T; van Delden OM; Dijkgraaf MG; van Gulik TM; van Hooft JE; van Laarhoven HW; Martin RC; Schoorlemmer A; Wilmink JW; van Lienden KP; Busch OR; Besselink MG
    Ann Surg Oncol; 2017 Sep; 24(9):2734-2743. PubMed ID: 28560601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
    Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
    Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
    Lorgis V; Chauffert B; Gentil J; Ghiringhelli F
    Anticancer Res; 2012 Sep; 32(9):4125-30. PubMed ID: 22993372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
    Ychou M; Viret F; Kramar A; Desseigne F; Mitry E; Guimbaud R; Delpero JR; Rivoire M; Quénet F; Portier G; Nordlinger B
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):195-201. PubMed ID: 17901955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.